SYRE · Spyre Therapeutics, Inc.
AI read · Good for SYRE
The AI's read
That is a more favorable outside view of Spyre. The report gives no new company results, so this is an analyst's opinion rather than a change in Spyre's reported business.
Deutsche Bank raised its price target for Spyre Therapeutics to $141 from $123 and still recommends buying.
Good for SYRE
Deutsche Bank raised its share target from $123 to $141 and kept its Buy rating. This is a favorable analyst view, though the report gives no new company results.
Get alerts for SYRE
Follow Spyre Therapeutics, Inc. (SYRE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SYREFree on the App Store and Google Play, or on the web.